Abstract A significant association has been reported between a common variant in the angiotensinogen gene (AGT), allele T235, and essential hypertension. In subsequent work, it was found that another variant, the presence of an adenine instead of a guanine 6 bp upstream from the initiation site of transcription, was in absolute linkage disequilibrium with T235. The nucleotide substitution at the Ϫ6 position affected the formation of DNA-protein complexes in gel mobility shift assays and the basal transcription of AGT in transactivation experiments. We have further examined the potential impact of this polymorphism on AGT promoter function. In ultraviolet cross-linking analysis, 150-and 75-kDa proteins bound to the AGT proximal promoter. The possible involvement of factors that bind to GC-rich domains, including Sp1, Sp3, and AP2, was not supported by gel mobility shift assays. Screening an expression library with a double-stranded DNA segment centered on Ϫ6 led to the isolation of cDNA clones encoding the YB1 protein. The specificity of the interaction of YB1 with the proximal promoter of AGT was verified by Southwestern blotting and gel mobility shift assays. In cotransfection experiments, YB1 reduced basal AGT promoter activity in a dose-dependent manner. Although these observations suggest a possible role for YB1 in modulating AGT expression, this function is likely to occur in the context of complex interactions involving other nuclear factors. The work illustrates the challenge of developing a molecular understanding of the relationship between common genetic variants and conditions that are only partly caused by them.
Introduction
Although only partial causation can be expected of any genetic determinant of essential hypertension, the search is motivated by the hope that it will provide new leads to the pathophysiology of the condition. Genetic studies can incriminate genomic regions or even specific genes. The functional analysis of such genetic hints remains daunting, however.
Genetic linkage and association with the T235 allele of the angiotensinogen gene (AGT) support the hypothesis that molecular variation in the gene modulates individual predisposition to essential hypertension (Jeunemaitre et al. 1992 ; Kato et al. 1999; Kunz et al. 1997) . Such genetic inference, however, provides no functional clue. In subsequent analyses, a common variant in the proximal promoter of AGT, the substitution of adenine for guanine six nucleotides upstream from the initiation site of transcription, was found in quasi-absolute linkage disequilibrium with the T235 variant . Although no functional difference could be identified between recombinant proteins carrying the T235 or the M235 allele, the A/G (Ϫ6) polymorphism led to significant differences in both specific interactions with nuclear proteins and promoter activity in vitro .
The goal of the present study was to identify nuclear factors that can act in trans at the site of the A/G(Ϫ6) polymorphism and modulate the basal expression of AGT. Through screening of expression libraries, we identified a cDNA encoding YB1 protein. Further experiments suggest that the protein can bind to the proximal promoter of AGT and can modulate its function in vitro.
Methods

Plasmid construction for promoter studies
From one to four copies of a 23-mer oligonucleotide, centered on nucleotide Ϫ6 of AGT, and with either G (G23) or A (A23) at this site, were inserted upstream from the SV40 promoter/Luciferase reporter fusion gene, using the pGL2 vector (Promega, Madison, WI, USA). Similarly, from one to three copies of either G23 or A23 were placed upstream from the adenovirus major late promoter at the SalI cloning site of the pMT2 expression vector (Genetics Institute, Cambridge, MA, USA). An AGT promoter segment spanning nucleotides Ϫ256 to ϩ90, with G at the Ϫ6 position, was enzymatically amplified, and additional restriction enzyme sites were created during the amplification. After digestion with KpnI and HindIII, the AGT promoter segments were placed upstream from the Luciferase reporter in the promoterless pGL3-basic vector (Promega). All inserts were verified in their entirety by DNA sequencing.
Transfection and reporter assay
HepG2 cells were cotransfected with 1 µg test vector and 0.1 µg control vector encoding Renilla Luciferase (pRL-SV40, Promega) following a calcium phosphate protocol using modified bovine serum (MBS) (Stratagene, La Jolla, CA, USA). Briefly, the cells were plated onto 12-well plastic dishes at 1 ϫ 10 5 per dish, and cultured for 24h before transfection. At the time of transfection, the medium was changed to 6% MBS in Dulbecco's Modified Eagle's Medium (DME). Each experiment involved triplicate or quadruplicate dishes for each construct as well as positive and negative controls. Twenty-four hours following transfection, the cells were harvested with a lysis buffer (Promega), and reporter activity was measured using a Dual-Luciferase Reporter Assay System in a luminometer (Promega).
Gel mobility shift assay Nuclear extract from HepG2 cells was prepared as described (Dignam 1983 ). Synthetic single-or doublestranded oligonucleotides labeled with [γ- 32 P] ATP by a kination reaction and then purified on 8% native polyacrylamide gels were used as probes in gel mobility shift assay as described (Giarabedian et al. 1993) . The binding reaction (20 µl) contained 10mM hydroxyethylpiperazine ethanesulfonic acid (HEPES) (pH 7.9), 5 mM MgCl 2 , 1 mM ethylenediaminetetraacetate (EDTA), 0.5 mM dithiothreitol (DTT), 100 mM KCl, 10% glycerol, and 2 µg of polydeoxyinosinic-deoxycytidylic acid. Nuclear extract (5 µg) was preincubated with the binding buffer on ice for 20 min, followed by incubation with radiolabeled probe at 25°C for 15 min. The binding reaction was resolved on a 4% native polyacrylamide gel in 0.5X Tris-borate ϩ EDTA buffer. After electrophoresis at 200 V for 2h, the gels were dried and exposed to Kodak XAR film at Ϫ80°C. Competition experiments were performed by adding a 100-fold molar excess of unlabeled single-or double-stranded oligonucleotides to the preincubation mixture. The sense single-stranded G(A)23 oligonucleotide was 5Ј-GTGACC CGGCCG(A)GGGGAAGAAGC-3Ј, and the antisense single-stranded G(A)23 oligonucleotide was 5Ј-GCTTCTT CCCCC(T)GGCCGGGTCAC-3Ј. When indicated, antibodies against Sp1, Sp3, AP2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or YB1 (a gift from Dr. Jenny P.-Y. Ting, University of North Carolina, Chapel Hill, NC) were added to the preincubation mixture.
UV cross-linking
After gel mobility shift assay was performed as described earlier, the gel was removed, wrapped with Saran wrap, irradiated with UV at a wave length of 254 nm for 20 min, and placed on Kodak XAR film for 4-5 h at room temperature. The retarded bands were excised and boiled in a sample buffer of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for 2-3 min. The samples were loaded and separated on 8% SDS-PAGE gels followed by autoradiography.
Expression cloning
A λ-gt11 human leukemia library from the MOLT4 cell line and a λ-gt11 human placenta cDNA expression library (Clontech, Palo Alto, CA, USA) were screened for a binding factor with the radiolabeled G23 oligonucleotide, proceeding through isopropyl thiogalactoside (IPTG) induction of fusion proteins, guanidinium denaturation/ renaturation, and hybridization with radiolabeled DNA probes as described by Singh et al. (1988) . Positive clones were subcloned into pBluescript-SK (ϩ), and sequenced.
Preparation of GST/YB1 fusion protein
The GST/YB1 fusion protein was produced using the expression vector pGEX2T (Amersham-Pharmacia Biotech, Piscataway, NJ, USA) including the entire coding sequence of YB1, which was a gift from Dr. Jenny P.-Y. Ting. The bacterial transformants were grown to an optical density of 0.6 to 0.8 at 600 nm and thereafter induced with 1 mM IPTG for 2 h at 37°C. The fusion proteins were purified with glutathione-Sepharose beads (Amersham-Pharmacia Biotech) and eluted with 50 mM Tris-HCl (pH 7.4) containing 15 mM reduced glutathione (Smith and Johnson 1988) .
Southwestern blots
Purified GST/YB1 fusion protein (100 ng) was separated on 10% SDS-PAGE gels and transferred to Hybond-C membrane (Amersham-Pharmacia Biotech) using a standard protocol. The membranes were subjected to guanidinium hydrochloride denaturation/renaturation as previously described (Vinson et al. 1988) . The membranes were blocked with 5% dry milk, and washed with a binding buffer (50 mM KCl, 10 mM HEPES at pH 7.0, 1.0 mM EDTA, 6.4 mM MgCl 2 , 1.0 mM DTT). The membranes were hybridized in binding buffer containing 0.25% dry milk with the indicated radiolabeled probe (1 ϫ 10 6 cpm/ml) for 8h at room temperature. Following three washes with binding buffer for 10-15 min, autoradiography was performed at Ϫ70°C.
Coexpression of YB1 with an AGT promoter-reporter construct
The entire coding sequence of human YB1 was placed under the control of the major late promoter of adenovirus in the expression vector pMT2 to generate the pMT2/YB1 construct. The promoter segment encompassing nucleotides Ϫ256 to ϩ90 of the human AGT gene was inserted upstream from the Firefly Luciferase reporter gene in the pGL3 vector (Promega) to generate the pAGT/Luc vector. HepG2 cells were cotransfected with pAGT/Luc (1µg/well) and pMT2/YB1 (0, 0.5, 1, and 2 µg/well) using an MBS mammalian transfection kit (Stratagene). The total amount of transfected DNA was kept constant by the addition of pMT2 plasmid. In all transfections, the plasmid pRL-SV40 (Promega), encoding Renilla Luciferase, was included as an internal control. Luciferase activity was measured using a Dual-Luciferase Reporter Assay System (Promega).
Results
Effects of G23 and A23 tandem repeats on transactivation of core promoters To test for a transcriptional effect of the DNA segment encompassing nucleotide Ϫ6 of AGT, we performed two series of transactivation experiments. First, HepG2 cells were transfected with reporter plasmids with one to four tandem repeats of either the G23 or the A23 oligonucleotide inserted upstream from an SV40 promoter-Luciferase fusion gene in the pGL2 vector (Promega). A direct, positive relationship was observed between reporter activity and number of copies of either G23 or A23 segments (Fig.  1a) , with no apparent difference between the two sequences. In a second series of experiments, competition for binding of nuclear factors was tested by cotransfecting a plasmid carrying a fusion gene consisting of the AGT promoter segment spanning nucleotides Ϫ256 to ϩ90 and the Firefly Luciferase coding sequence, together with plasmids containing from one to three repeats of either G23 or A23 placed in front of an adenovirus major late promoter with no coding insert. Although reporter expression increased when G23 was used as a competitor, no difference was observed with A23 (Fig. 1b) .
Characterization of a factor that binds to the proximal promoter of AGT Factors acting in trans on the AGT promoter segment spanning the Ϫ6 region were examined by ultraviolet (UV) cross-linking of the two protein complexes revealed by gel retardation assays . Cross-linking of the upper band (U in Fig. 2 ) resulted in two proteins with estimated molecular weights of 150 and 75 kDa, respectively (Fig. 2) . The lower band (L in Fig. 2 ) yielded molecules of 80 and 50kDa, respectively. This complex has previously been recognized as nonspecific and identified as the Ku autoantigen, the 80-kDa component corresponding to the p70 DNA-binding subunit .
The high GC content of the Ϫ6 region suggested a possible involvement of known GC-binding factors such as Sp1, Sp3, and AP2. To address this issue, we examined whether specific antibodies could affect either binding or mobility of electrophoretically retarded complexes. As shown in Fig. 3 , none of the three antibodies interfered with the retardation experiments.
Isolation of cDNA encoding a protein that binds to the AGT proximal promoter To isolate cDNA clones encoding factors binding to the proximal promoter of AGT, we screened λ-gt11 human leukemia and placenta libraries with radiolabeled doublestranded G23 oligonucleotide. An oligonucleotide containing the Oct-1 binding consensus sequence was used to eliminate nonspecific signals in a secondary screen. Two clones, one from each library screened, met the criteria for specific binding on such secondary screening. Complementary DNA fragments were subcloned into pBluescript-SK(ϩ) and sequenced. Sequence analysis revealed that these two clones had overlapping sequences, and the protein encoded by the open reading frame was identified as human YB1.
YB1 binds to the AGT proximal promoter
Recombinant protein was expressed in Escherichia coli as a fusion protein with glutathione-S-transferase (GST/YB1) to evaluate the binding activity of YB1. YB1 has been previously reported to bind both double-and single-stranded DNA in a sequence-specific manner (Bayarsaihan et al. 1996; Hasegawa et al. 1991; Kolluri et al. 1992; MacDonald et al. 1995; Mertens et al. 1997; Ohmori et al. 1996) . We performed gel mobility shift assay and Southwestern blots using double-and single-stranded G23 oligonucleotides. All precautions were taken to prevent the generation of single- 3, and 4) . By contrast, a protein complex bound to Sp1-specific oligonucleotide exhibited supershifting (b) in the presence of antiSp1 antibody, whereas the same complex was markedly reduced (d) on addition of Sp3 antibodies (lanes 6 and 7) . A protein complex bound to AP2 oligonucleotide exhibited supershifting (e) in the presence of anti-AP2 antibodies (lanes 8 and 9) stranded DNA within the double-stranded probe. The gel mobility shift assay showed that GST/YB1 bound to antisense single-stranded G23 oligonucleotide with high affinity and bound to double-stranded G23 oligonucleotide with low affinity (Fig. 4a) . No binding was observed with sense single-stranded G23 oligonucleotide. No competition was observed when double-or single-stranded oligonucleotides containing binding sites for Sp1 or AP2 were included in the reaction as unlabeled competitors (data not shown). Southwestern blotting showed that GST/YB1 fusion protein bound to the double-stranded G23 oligonucleotide with high affinity and bound to antisense single-stranded G23 and the double-stranded SP1 oligonucleotide with low affinity (Fig. 4b) . The results of these experiments suggest that YB1 binds to G23 oligonucleotide in a sequence-specific manner. No difference in binding affinity of YB1 protein to G23 and A23 oligonucleotides was detected, however (data not shown). Furthermore, anti-YB1 antibodies failed to affect the binding or mobility of electrophoretically retarded complexes after incubation of G23 oligonucleotide with HepG2 nuclear extract (Fig. 4c) .
Cotransfection studies
To investigate whether YB1 can affect AGT transcription, we cotransfected HepG2 cells with plasmid carrying an AGT promoter-reporter fusion plasmid with G at position Ϫ6 and a pMT2/YB1 vector, placing the entire coding sequence of YB1 under control of the adenovirus major late promoter. Coexpression of YB1 led to decreased AGT-driven reporter activity in a dose-dependent manner (Fig. 5) . ss-G23(A), singlestranded G23 oligonucleotides in sense and antisense orientation respectively; ds-G23, doublestranded G23 oligonucleotide; ds-Oct1, nonspecific oligonucleotide encompassing the Oct-1 binding motif. b Binding of GST/ YB1 protein to G23 oligonucleotides after transfer to nylon membrane (Southwestern blotting). GST, GST protein alone; GST/YB1, fusion protein of GST and YB1; ds-Oct1, ds-SP1, double-stranded oligonucleotides encompassing the Oct-1 and the SP1 motif respectively; other notations are given in a. c Gel mobility shift assay in the presence or absence of anti-YB1 antibody. NE, nuclear extract; rYB1, recombinant YB1 fusion protein; anti-YB1, anti-YB1 specific antibody
Discussion
The challenge of identifying genetic factors underlying essential hypertension only begins with the inference of genetic linkage and allelic association. Because only partial causation is expected, analysis of functional significance at levels of integration ranging from molecular to organismic will prove necessary and difficult.
The initial hypothesis advanced by Jeunemaitre et al. (1992) was that a moderate but sustained increase in expression of AGT could, over time, account for disease predisposition. Smithies and Kim (1994) and Kim et al. (1995) have developed original transgenic manipulations to provide direct evidence in vivo that a modest increase in AGT gene expression could lead to a chronic increase in arterial pressure. Morgan et al. (1997) have shown that, in placental tissue collected from 39 women heterozygous for the M/ T(235) polymorphism, AGT mRNA encoding T235 was in significant excess over the M235 counterpart.
Although no functional differences could be detected between recombinant protein with either T or M at residue 235, the G/A(Ϫ6) polymorphism, in absolute disequilibrium with the M/T(235) polymorphism ), had to be tested formally for its potential significance. Initial studies have shown that the nucleotide substitution could indeed affect interaction with nuclear proteins and transcriptional activity of the gene in vitro . One of the hypotheses generated by this work was that at least two factors may interact with the DNA sequence surrounding the G/A(Ϫ6) polymorphism: although an activator may bind to both alleles, allele G(Ϫ6) may also show affinity for a competing factor, inducing relative inhibition as a net effect ). The present work may provide additional support for this hypothesis: (1) when short segments of the AGT core promoter encompassing this polymorphic site are placed in front of a core SV40 promoter, they lead to enhanced expression in a dosedependent fashion irrespective of the variant present at site Ϫ6 (Fig. 1a) ; (2) when segments encompassing site Ϫ6 are used as competitors in transactivation assays of the core AGT promoter, the A(Ϫ6) allele has no effect, whereas G(Ϫ6) appears to relieve relative inhibition in a dosedependent manner (Fig. 1b) .
The search for a factor binding to the Ϫ6 region by screening expression libraries with a specific DNA probe led to cloning of YB1. This protein was originally identified as a CCAAT box binding factor (Ozer et al. 1990; Tafuri and Wolffe 1990 ) and recent studies have revealed that its nucleic acid binding may not entirely be CCAAT dependent (Gai et al. 1992; Lenz et al. 1990; Sakura et al. 1988; Yan and I 1991) . No CCAAT motif can be identified in the vicinity of nucleotide Ϫ6 of AGT. YB1 has been shown to bind to single-stranded DNA (Bayarsaihan et al. 1996; Hasegawa et al. 1991; Kolluri et al. 1992; MacDonald et al. 1995; Mertens et al. 1997; Ohmori et al. 1996) , mRNA (Evdokimova et al. 1995) , and damaged DNA, suggesting pleiotropic effects on DNA repair, maintenance/regulation of chromatin architecture, and general mRNA packing (Wolffe 1993) . The specificity of the interaction between YB1 and the G23 oligonucleotide was supported by the lack of binding to Oct-1 oligonucleotide, previously validated and used as negative control in gel shift assay experiments ). This specificity is further supported by Southwestern blotting analysis and gel mobility shift assay with purified recombinant YB1 protein (Fig. 4) . Furthermore, the coexpression of YB1 reduces AGT promoter activity in a dose-dependent manner (Fig. 5) . Similar experiments involving other genes (Didier et al. 1988; Duh et al. 1995; Goldsmith et al. 1993; Mertens et al. 1997; Ohmori et al. 1996; Ting et al. 1994 ) have provided evidence that YB1 protein can modulate basal gene transcription through interaction with either double-or single-stranded DNA or with other transcription factors (Li et al. 1997; Raj et al. 1996) .
Several experiments, however, did not provide additional support for the hypothesis of a functional interaction between YB1 and AGT. No difference could be detected in the relative binding affinity of recombinant YB1 and the A23 and G23 oligonucleotides (data not shown). YB1 antibodies did not induce supershifting in gel retardation experiments, but not all antibodies do so under such conditions. Finally, the 50 kDa molecular weight of YB1 does not closely match the size of the complex revealed in our UV cross-linking experiments.
To conclude, we cloned YB1 as a factor that may interact with AGT in the region of the G/A(Ϫ6) polymorphism. Some observations support the hypothesis that this interaction may be functional, but not all tests performed support this conclusion. The study illustrates the challenge of relating polymorphism to function at the molecular level when differences in degree, rather than gain or loss of function, are expected. The existence of other variants in the gene, in various degrees of linkage disequilibrium with the G/A (Ϫ6) polymorphism (Nakajima et al., manuscript in preparation) including variants at site Ϫ20 ) and ϩ67 (Ishigami et al. 1999) , and our own unpublished observations suggests that the mechanism by which AGT variation may affect its functional expression may be far more complex than initially anticipated.
